PBM
HEALTHCAREPsyence Biomedical Ltd
Live · NASDAQ · May 9, Close
What's Moving PBM Today?
No stock-specific AI insight has been generated for PBM yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$5.93
Fundamentals
Trading
PBM News
20 articles- Weekly Roundup on the Cannabis Sector & Psychedelic SectorYahoo Finance·Apr 27, 2026
- FDA Fast-Tracks Psychedelic Drug Research Following Trump Directive; Psychedelic Drug Makers GainYahoo Finance·Apr 24, 2026
- Psyence BioMed Initiates Patient Dosing in Phase IIb Trial Evaluating NPX-5 for Adjustment DisorderYahoo Finance·Apr 23, 2026
- Psyence BioMed Positioned as World's only Licensed Pharmaceutical Grade Ibogaine Supplier at SourceYahoo Finance·Apr 20, 2026
- Psychedelic Shares Rise Following Trump's Executive Order to Accelerate Treatments for Serious Mental IllnessYahoo Finance·Apr 20, 2026
- Trump Trade: President to sign order on psychedelic used for PTSDYahoo Finance·Apr 17, 2026
- Sector Update: Health Care Stocks Advance Late AfternoonYahoo Finance·Apr 17, 2026
- Sector Update: Health Care Stocks Higher Friday AfternoonYahoo Finance·Apr 17, 2026
- Top Midday GainersYahoo Finance·Apr 17, 2026
- Psyence BioMed Welcomes U.S. Executive Action to Advance Research into IbogaineYahoo Finance·Apr 17, 2026
- Pacific Bay & Aurwest Sign Weaver Gold Property Definitive Option/JV AgreementYahoo Finance·Apr 14, 2026
- Psyence BioMed Expands Australian Clinical Site Network to Five Sites, Advancing NPX-5–Supported Clinical ActivitiesYahoo Finance·Apr 8, 2026
- Corporate Update: Psyence BioMed Advances Vertically Integrated Pharmaceutical Platform Following PsyLabs Export MilestoneYahoo Finance·Mar 11, 2026
- Psychedelic: Helus Pharma reports HLP004 Phase 2 signal detection study resultsYahoo Finance·Mar 6, 2026
- Psyence BioMed Announces Export of GMP-Manufactured Natural Psilocybin (NPX-5) to Australia for Ongoing Phase IIb Clinical TrialYahoo Finance·Mar 3, 2026
- Psyence BioMed Announces Exercise of Put Option by PsyLabs and Strategic Equity InvestmentYahoo Finance·Feb 20, 2026
- Psyence BioMed Announces Results of Annual and Special Meeting of ShareholdersYahoo Finance·Feb 17, 2026
- Psyence BioMed Approves Put Option Agreement with PsyLabs to Secure Strategic Supply and Strengthen Commercialization PathwayYahoo Finance·Feb 13, 2026
- Psyence BioMed Announces Settlement of Shareholder LitigationYahoo Finance·Feb 11, 2026
- Psyence BioMed Announces Effective Date for 1-for-6.25 Reverse Stock SplitYahoo Finance·Jan 28, 2026
All 20 articles loaded
Price Data
52-Week Range
$5.93
Fundamentals
Trading
About Psyence Biomedical Ltd
Psyence Biomedical Ltd. (PBM) is a pioneering biotechnology company dedicated to unlocking the therapeutic potential of psychedelic compounds, specifically in the realms of mental health and wellness. By employing a vertically integrated approach, Psyence excels in the cultivation, formulation, and clinical research of psilocybin and other psychedelic substances, with the objective of developing innovative therapies to address pressing mental health issues. Supported by a strong intellectual property portfolio and a promising clinical pipeline, the company is well-positioned to capitalize on the growing acceptance of psychedelics in healthcare, addressing the urgent demand for accessible and effective mental health solutions.